Supplementary Data 1 from Spatiotemporal Quantification of HER2-targeting Antibody–Drug Conjugate Bystander Activity and Enhancement of Solid Tumor Penetration
Qing Wei(Chinese Academy of Sciences), Xiangdong Cheng(Zhejiang Cancer Hospital), Jianmin Fang(Tongji University), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Takaya Shimura(Nagoya City University), Xuefei Tian(Shanghai Institute of Materia Medica), Mengyang Fan(Hangzhou Academy of Agricultural Sciences), Ziwen Zhang(Zhejiang Cancer Hospital), Jiahui Chen(Chinese Academy of Sciences), Peng Guo(Lanzhou University), Can Hu(Zhejiang Cancer Hospital), Jiayu Zhu(Zhejiang Chinese Medical University), Le Yang(Zhejiang Cancer Hospital), Yuchao Zhang(Sun Yat-sen University), Teng Yang(Zhejiang University of Science and Technology), Jinchao Wang(Hangzhou Academy of Agricultural Sciences)
Cited by 0
Related Papers
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
|癌症：英文版|2023|412
Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model
|Proceedings of the National Academy of Sciences|2000|392